Back to FGEN Stock Lookup
Pages: 1 2 »» Last Page

FibroGen (FGEN) – Globe Newswire

Apr 6, 2021 07:50 PM FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021
Apr 6, 2021 04:01 PM FibroGen Provides Additional Information on Roxadustat
Mar 16, 2021 07:00 AM FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
Mar 1, 2021 04:01 PM FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 1, 2021 04:01 PM FibroGen Provides Regulatory Update on Roxadustat
Feb 18, 2021 07:00 AM FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
Feb 12, 2021 07:00 AM FibroGen to Present at Upcoming Investor Conferences
Dec 22, 2020 07:00 AM FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2
Dec 18, 2020 04:59 PM FibroGen Provides Regulatory Update on Roxadustat
Dec 2, 2020 07:00 AM FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting
Dec 1, 2020 08:00 AM FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer
Nov 27, 2020 07:00 AM Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
Nov 6, 2020 07:00 AM FibroGen to Present at Upcoming Investor Conferences
Nov 5, 2020 04:01 PM FibroGen Reports Third Quarter 2020 Financial Results
Oct 29, 2020 07:00 AM FibroGen to Report Third Quarter 2020 Financial Results
Oct 22, 2020 10:08 AM FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)
Oct 14, 2020 07:00 AM FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
Sep 8, 2020 07:00 AM FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer
Sep 1, 2020 07:00 AM FibroGen to Present at Upcoming Investor Conferences
Aug 11, 2020 07:00 AM FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy
Aug 6, 2020 04:02 PM FibroGen Reports Second Quarter 2020 Financial Results
Aug 6, 2020 04:01 PM FibroGen Announces New Appointments to its Board of Directors
Jul 23, 2020 07:00 AM FibroGen to Report Second Quarter 2020 Financial Results
Jun 23, 2020 07:00 AM FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
Jun 22, 2020 07:00 AM FibroGen Appoints Thane Wettig as Chief Commercial Officer
Jun 8, 2020 05:00 PM FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress
Jun 8, 2020 07:00 AM FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
May 27, 2020 07:00 AM FibroGen to Present at Upcoming Investor Conferences
May 21, 2020 07:00 AM European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat
May 8, 2020 07:00 AM FibroGen to Present at Bank of America Securities 2020 Health Care Conference
May 7, 2020 04:01 PM FibroGen Reports First Quarter 2020 Financial Results
Apr 24, 2020 07:00 AM FibroGen To Report First Quarter 2020 Financial Results
Apr 20, 2020 07:00 AM FibroGen Reports UK Court Ruling
Mar 2, 2020 04:01 PM FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
Feb 18, 2020 07:00 AM FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results
Feb 11, 2020 05:00 PM FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease
Feb 11, 2020 08:00 AM FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference
Jan 6, 2020 07:00 AM FibroGen Names Enrique Conterno as Chief Executive Officer
Dec 23, 2019 07:00 AM FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease
Dec 2, 2019 07:00 AM FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
Nov 11, 2019 04:01 PM FibroGen Reports Third Quarter 2019 Financial Results
Nov 8, 2019 02:10 PM FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
Nov 7, 2019 04:39 PM FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease
Nov 4, 2019 07:00 AM FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
Oct 23, 2019 07:00 AM FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer  
Oct 11, 2019 10:58 AM Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019
Oct 7, 2019 05:57 PM FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine
Sep 30, 2019 08:00 PM FibroGen Receives One of China Pharmaceutical Industry’s Highest Awards for Clinical Innovation for Roxadustat
Sep 30, 2019 07:00 AM FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis
Sep 26, 2019 07:00 AM FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
Pages: 1 2 »» Last Page

Back to FGEN Stock Lookup